Abstract:Targeted protein degradation (TPD) has emerged as a prominent and vital strategy for therapeutic intervention of cancers and other diseases. One such approach involves the exploration of proteolysis targeting chimeras (PROTACs) for the selective elimination of disease-causing proteins through the innate ubiquitin-proteasome pathway. Due to the unprecedented achievements of various PROTAC molecules in clinical trials, researchers have moved towards other physiological protein degradation approaches for the targeted degradation of abnormal proteins, including lysosome-targeting chimeras (LYTACs), autophagy-targeting chimeras (AUTACs), autophagosome-tethering compounds (ATTECs), molecular glue degraders, and other derivatives for their precise mode of action. Despite numerous advantages, these molecules face challenges in solubility, permeability, bioavailability, and potential off-target or on-target off-tissue effects. Thus, an urgent need arises to direct the action of these degrader molecules specifically against cancer cells, leaving the proteins of non-cancerous cells intact. Recent advancements in TPD have led to innovative delivery methods that ensure the degraders are delivered in a cell- or tissue-specific manner to achieve cell/tissue-selective degradation of target proteins. Such receptor-specific active delivery or nano-based passive delivery of the PROTACs could be achieved by conjugating them with targeting ligands (antibodies, aptamers, peptides, or small molecule ligands) or nano-based carriers. These techniques help to achieve precise delivery of PROTAC payloads to the target sites. Notably, the successful entry of a Degrader Antibody Conjugate (DAC), ORM-5029, into a phase 1 clinical trial underscores the therapeutic potential of these conjugates, including LYTAC-antibody conjugates (LACs) and aptamer-based targeted protein degraders. Further, using bispecific antibody-based degraders (AbTACs) and delivering the PROTAC pre-fused with E3 ligases provides a solution for cell type-specific protein degradation. Here, we highlighted the current advancements and challenges associated with developing new tumour-specific protein degrader approaches and summarized their potential as single agents or combination therapeutics for cancer.

PROTAC targeted protein degraders: the past is prologue

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Degraders Upgraded: The Rise of PROTACs in Haematological Malignancies

[Induced degradation of proteins by PROTACs and other strategies: towards promising drugs]

Beyond Canonical PROTAC: Biological Targeted Protein Degradation (Biotpd)

Expanding the Horizons of Targeted Protein Degradation: A Non-Small Molecule Perspective

Recent advances in targeted protein degraders as potential therapeutic agents

Targeted protein degradation: advances in drug discovery and clinical practice

From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies

Recent breakthroughs in innovative elements, multidimensional enhancements, derived technologies, and novel applications of PROTACs

Powering up targeted protein degradation through active and passive tumour-targeting strategies: Current and future scopes

Targeted protein degradation: expanding the toolbox

Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation

Targeted protein degradation: mechanisms, strategies and application

Recent Advances in PROTACs for Drug Targeted Protein Research

Novel approaches to targeted protein degradation technologies in drug discovery

PROTACs: A Novel Strategy for Cancer Drug Discovery and Development

Emerging TACnology: Heterobifunctional Small Molecule Inducers of Targeted Posttranslational Protein Modifications